The last time I posted on Travere Therapeutics (TVTX), in September 2025, I gave the stock a buy rating. I was discussing the fact that the FDA had opted not to convene an Advisory Committee meeting ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Travere Therapeutics, Inc. (TVTX) had its molecule FILSPARI approved in both IgA nephropathy, or IgAN, and focal segmental glomerulosclerosis, or FSGS. The question now has shifted from clinical ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Travere TherapeuticsTVTX shares crashed Tuesday as investors digested a delay for its drug, Filspari, in treating a serious kidney disease. The company said Tuesday the Food and Drug Administration ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032 (the “Notes”) ...
Travere TherapeuticsTVTX is Thursday's IBD Stock Of The Day. Shares are lingering around a buy zone following a big earnings gap-up and a new approval for its bread-and-butter drug, Filspari. Filspari ...
Travere cannot predict the magnitude of such market activity or the overall effect it will have on the price of the Notes or Travere’s common stock. J.P. Morgan, Jefferies, and Leerink Partners are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results